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Abstract
Background: MYH11 (also known as SMMHC) encodes the smooth-muscle myosin heavy chain,
which has a key role in smooth muscle contraction. Inversion at the MYH11 locus is one of the
most frequent chromosomal aberrations found in acute myeloid leukemia. We have previously
shown that MYH11 mutations occur in human colorectal cancer, and may also be associated with
Peutz-Jeghers syndrome. The mutations found in human intestinal neoplasia result in unregulated
proteins with constitutive motor activity, similar to the mutant myh11 underlying the zebrafish
meltdown phenotype characterized by disrupted intestinal architecture. Recently, MYH1 and MYH9
have been identified as candidate breast cancer genes in a systematic analysis of the breast cancer
genome.
Methods: The aim of this study was to investigate the role of somatic MYH11 mutations in two
common tumor types; breast and prostate cancers. A total of 155 breast cancer and 71 prostate
cancer samples were analyzed for those regions in MYH11 (altogether 8 exons out of 42 coding
exons) that harboured mutations in colorectal cancer in our previous study.
Results: In breast cancer samples only germline alterations were observed. One prostate cancer
sample harbored a frameshift mutation c.5798delC, which we have previously shown to result in a
protein with unregulated motor activity.
Conclusion: Little evidence for a role of somatic MYH11 mutations in the formation of breast or
prostate cancers was obtained in this study.
Background
MYH11 (also known as SMMHC) encodes the smooth-
muscle myosin heavy chain and belongs to the family of
conventional myosins. The well-characterized biological
function of myosins is their ability to use the energy of
ATP hydrolysis to move actin filaments and produce mus-
cle force. Recently, myosins have been implicated in a
variety of other intra-cellular functions, including cell
migration, adhesion, control of cell shape, and membrane
traffic [1], as well as in cell-signaling pathways such as
interaction with Rho [2] and the pro-apoptotic protein
Bmf (BCL2-modifying factor) [3]. In yeast, myosin 5 has
Published: 17 September 2008
BMC Cancer 2008, 8:263 doi:10.1186/1471-2407-8-263
Received: 23 April 2008
Accepted: 17 September 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/263
© 2008 Alhopuro et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:263 http://www.biomedcentral.com/1471-2407/8/263
Page 2 of 5
(page number not for citation purposes)
been shown to orientate the mitotic spindle making it piv-
otal in establishment of cell polarity [4]. Furthermore,
several recent publications have shown the significance of
nuclear actin and myosin I in transcription [1,5].
Inversion at the MYH11 locus inv(16)(p13q22) is one of
the most frequent chromosomal translocations found in
acute myeloid leukemia (AML) and accounts for approxi-
mately 8% of all AML cases, especially those of the M4Eo
subtype [6]. The inversion results in fusion of the first four
to five exons of core binding factor β (CBFβ) and the C-
terminal tailpiece of the MYH11 gene and formation of an
oncogenic chimeric protein [6].
Recently, myh11 was identified as the predisposing gene
for the zebrafish recessive lethal meltdown phenotype. The
meltdown mutants develop cystic expansions of the poste-
rior intestine and expanded connective tissue reminiscent
of human juvenile polyposis and Peutz-Jeghers syndrome
polyps. The mutation observed in the germline of these
fish is located in a highly conserved area of the gene and
it leads to constitutive activation of the ATPase function,
resulting in disruption of the smooth muscle adjacent to
posterior intestine [7].
We have previously identified MYH11 as a driver gene in
human colorectal cancer [8]. We identified a somatic
frameshift mutation (c.5798delC) in the MYH11 gene in
55% of colorectal cancers (CRCs) with microsatellite
instability. MYH11 mutations were also found in one mic-
rosatellite stable CRC (altogether 30 MSS CRCs analyzed)
and in the germline of one patient with Peutz-Jeghers syn-
drome. Functional assays demonstrated that the muta-
tions (R500L, K1044N and c.5798del/insC) identified in
MYH11 in colorectal neoplasia resulted in unregulated
proteins with actin-activated motor activity, similar to the
mutant myh11 underlying the zebrafish meltdown pheno-
type [7]. We suggested that MYH11 could play a role in
tumor formation by disturbing stem cell differentiation
process or through effects on cellular energy balance.
The aim of the current work was to investigate the possible
role of somatic MYH11 mutations in two other common
cancer types, breast and prostate cancer.
Methods
Breast cancer samples
A total of 155 breast cancer DNA samples were available
for the study. The samples were derived from patients
unselected for a possible family history of cancer and
diagnosed with mammary gland adenocarcinoma
between 1988 and 1994 at the Oulu University Hospital.
The individuals had a mean age at diagnosis of 55 years
(range 29–89 years) [9]. Tumor samples were evaluated
by a pathologist prior to DNA extraction and contained at
minimum 30% of tumor cells. A total of 34 samples
(21.9%) had a tumor content < 50% (approximately 40%
of tumor cells). On average the tumor cell content was
50–70%, which should enable detection of somatic muta-
tions by sequencing. Patients gave their informed consent,
and approval to perform the study was obtained from the
Ethical Board of the Northern Ostrobothnia Health Care
District (11/2000, 88/2000) and the Finnish Ministry of
Social Affairs and Health (Dnr 46/07/98).
Prostate cancer samples
Genome Phi-amplified (GenomiPhi Amplification kit,
Amersham, GE Healthcare, UK) unselected prostate
tumour samples (n = 71) from the Tampere region were
analysed. Of these 71 samples, 30 were prostatectomy
specimens from previously untreated patients. 14 hor-
mone-refractory specimens were obtained from transure-
thral resection. These patients had been treated by
androgen withdrawal, on average, for 38 months (range:
15–68 months). In addition, 6 benign prostate hyperpla-
sia specimens, 16 prostate cancer xenografts (LuCaP 23.1,
23.8, 35, 35V, 49, 58, 69, 70, 73, 77, 78, 81, 92.1, 96, 105,
115, kindly provided by Dr. Robert Vessella, University of
Washington, Seattle, WA, USA), and 5 prostate cancer cell
lines (DU145, LAPC4, LNCaP, PC-3 and 22Rv1) were
available. DU145, LNCaP, PC-3 and 22Rv1 were obtained
from the American Type Culture Collection (ATCC, Man-
assas, VA, USA), and LAPC4 was kindly provided by Dr.
Charles Sawyers (MSKCC, New York, NY, USA). Prior to
DNA extraction the samples were evaluated by a patholo-
gist to confirm sufficient content of malignant tissue. All
tumor samples contained >60% of malignant cells. The
use of clinical tumor material has been approved by the
Ethical Committee of Tampere University Hospital. All
patients participating in this study gave informed consent.
PCR and sequencing
MYH11 (NM_002474 and NM_022844) exons 9, 12, 24,
27, 28, 29, 38 and 40 (isoform SM2) were analyzed using
PCR and genomic sequencing. The first coding exon was
termed exon 1. MYH11 encodes almost 2000 amino acids
(42 exons), and targeted mutation analysis was performed
focusing only on the regions that were important in color-
ectal tumor formation. The mutations which were previ-
ously functionally examined were located in exons 12
(R500L), 24 (K1044N) and 40 (SM2, c.5798del/insC) [8].
Sequencing primers have been described previously [8].
PCRs were performed in 25 μl volume containing 20 ng of
genomic DNA, 1× PCR buffer (Applied Biosystems, AB,
Foster City, California), 200 μmol/l each dNTP
(Finnzymes, Espoo, Finland), 0.25 μmol/l both primers,
and 1.25 units AmpliTaq Gold DNA polymerase. Samples
were purified using ExoSAP-IT PCR purification kit (USB
Corporation, Cleveland, Ohio), and sequenced using ABBMC Cancer 2008, 8:263 http://www.biomedcentral.com/1471-2407/8/263
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3730 BD3.1 sequencing chemistry and 5.1 sequencing
analysis software (Applied Biosystems, Branchburg, NJ).
Genomic (un-amplified) DNA was available from the
prostate samples for further analyses.
Results
Most of the studied MYH11 exons were successfully ana-
lyzed in 80–100% of samples, with a few exceptions. In
prostate cancers, exon 9 was successfully analyzed only in
33% of samples due to technical problems, and in breast
cancers results from exon 24 sequencing were derived
from 73% of cases. As somatic mutations may be missed
due to normal tissue contamination, only sequence traces
with no background signal were scored successful to ena-
ble detection of even small mutation peaks.
Analysis of 155 breast cancer samples for selected MYH11
exons revealed no somatic alterations. A heterozygous
missense alteration A1072T was detected in one patient
with breast cancer, which to our knowledge has not been
reported in previous studies (Table 1). This alteration was
detected also in the respective germline sample. The sig-
nificance of A1072T was not evaluated further and
remains unknown, although it is likely a rare polymor-
phism. A missense change D1066N was detected in two
breast cancer samples and in the corresponding normal
tissue samples in heterozygosity. This variant was
observed also in our previous work in the germline DNA
of Finnish patients with colorectal cancer and is presuma-
bly a polymorphism [8].
A heterozygous alteration K1247K was found in one pros-
tate cancer cell line (Table 1). Unfortunately, no corre-
sponding normal tissue was available and this silent
change was not studied further. One prostate cancer sam-
ple harbored a frameshift mutation c.5798delC (Table 1)
in a microsatellite tract of 8 cytosine units, which we have
previously shown to occur frequently in MSI CRC and to
result in a protein with unregulated actin-activated motor
activity. The sample was re-analyzed using genomic (un-
amplified) DNA to confirm the result. Somatic origin of
the frameshift mutation or microsatellite-status of this
prostate specimen could not be determined due to lack of
normal tissue sample. However, in a previous compara-
tive genomic hybridization study [10] the sample showed
little signs of chromosomal instability, which could be
suggestive of MSI. The sample (LuCaP73) harboring the
candidate somatic MYH11  frameshift mutation was a
xenograft specimen originating from a hormone-refrac-
tory prostate cancer. No other somatic changes were
detected in prostate cancer samples.
Discussion
Breast and prostate carcinomas are among the most com-
mon cancers in Western countries. The efforts aiming to
identify cancer-specific somatic mutations in these cancer
types may ideally provide clues to understanding the cel-
lular processes underlying tumor development and lead
to diagnostic and therapeutic advances.
Myosins have a well-characterized biological function in
the use the energy of ATP hydrolysis to move actin fila-
ments and produce muscle force, but are implicated also
in a variety of other cellular functions, many of which are
relevant for cancer formation [1]. We have previously
shown that somatic mutations in MYH11, which result in
unregulated proteins with constitutive activity, contribute
to CRC formation. Recently, MYH1  encoding skeletal
muscle myosin heavy polypeptide 1 and MYH9 encoding
non-muscle myosin heavy chain type A, were identified as
candidate breast cancer genes in systematic analyses of the
breast cancer genome [10-12]. Here we have extended the
analysis of the role of myosins in tumor development and
analyzed sizable sets of breast and prostate cancers for
Table 1: Alterations detected in 155 breast carcinomas and 71 prostate carcinomas (50 primary tumors, 16 xenografts).
Alteration No of samples Type of alteration (Reference)
D1066N** 2 Breast ca Germline polymorphism [8]
A1072T** 1 Breast ca Germline polymorpism (this study)
A1234T* 28 Prostate ca Germline polymorphism (Ensembl)
61 Breast ca
K1247K** 1 Prostate ca Unknown (this study)
V1289A* 3 Prostate ca Germline polymorphism (Ensembl)
6 Breast ca
L1323L * 1 Prostate ca Germline polymorphism (Ensembl)
10 Breast ca
A1839A** 7 Breast ca Germline polymorphism [8]
1 Prostate ca
c.5798delC 1 Prostate ca Candidate somatic mutation
* Reported polymorphism http://www.ensmbl.org
** Not repoted in Ensembl Genome BrowserBMC Cancer 2008, 8:263 http://www.biomedcentral.com/1471-2407/8/263
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somatic mutations in the key regions of the MYH11 gene
(altogether 8 out of 42 coding exons, covering approxi-
mately 18% of the coding region).
We analyzed breast and prostate cancer samples for those
MYH11  regions that harbored somatic mutations in
CRCs. Especially exons 12, 24 and 40 (SM2) were of inter-
est, as we have demonstrated by functional analysis that
mutations in these areas result in molecules lacking phos-
phorylation-dependent regulation. Based on current
structural models of myosin regulation, most mutations
in the MYH11 head or in the rod domain would not be
expected to abolish regulation [13]. Therefore it is possi-
ble that mutations only in certain regions of MYH11 con-
tribute to tumor formation. The strategy was to analyze
the regions with the greatest potential for discovery of
mutations in a large set of non-CRC tumors.
In this study, no somatic MYH11 mutations were found in
breast cancer samples. In prostate cancers, an ATPase acti-
vating candidate somatic MYH11 mutation (c.5798delC)
was identified in one xenograft sample only. This muta-
tion may have occurred by chance and therefore more evi-
dence is needed to establish whether MYH11 has a role in
prostate cancer development. However, c.5798delC
seems to occur infrequently in prostate cancers. The nega-
tive results are unlikely to be due to normal tissue contam-
ination, as the tumor cell content was typically >50%.
Certain somatic mutations, undetectable by sequencing,
may have been missed in this study. Based on this work,
we cannot exclude the occurrence of mutations in other
regions of MYH11  and further studies are needed. It
would be of interest to study smaller sets of breast and
prostate tumors for the entire coding region of MYH11.
Nevertheless, the study suggests that somatic MYH11
mutations are not frequent in breast and prostate cancer.
Conclusion
In conclusion, somatic mutations in the regions of
MYH11 that are important for colorectal tumor formation
are not frequent in breast or prostate cancers.
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